Immunotherapy drugs for advanced anal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests two immunotherapy drugs—pembrolizumab and lenvatinib—for people with advanced anal cancer that has spread or come back. The goal is to see if these drugs can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced anal cancer (stage 4) that cannot be removed by surgery.
- You must have already had at least one round of chemotherapy, or be unable to receive it.
- You must be at least 18 years old and able to do most daily activities (ECOG score 0, 1, or 2).
- Your organs (kidneys, liver, bone marrow, heart) must be working well enough, as shown by blood and heart tests.
- If you are a person who can become pregnant, you must agree to use effective birth control during and for a time after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an adaptive, image-guided radiation plan for anal canal squamous-type cancers. It may help deliver effective treatment while adjusting the radiation based on how your body and tumor respond.
This study tests a combination of chemotherapy, radiation therapy, and an immunotherapy drug (anti-PD-1 antibody) for anal squamous cell cancer. The trial enrolls patients at different stages of disease to see if adding immunotherapy improves outcomes.
This trial tests a combination of two drugs, lenvatinib and pembrolizumab, for people with anal or rectal cancer that has spread or cannot be removed and has worsened after initial treatment. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 trial studies a combination of immunotherapy (spartalizumab), chemotherapy (mDCF includes docetaxel), and radiation to treat metastatic or returning anal squamous cell cancer. It may help shrink tumors and improve outcomes compared with standard approaches, but eligibility is strict to keep participants safe.
This trial tests a combination of the immunotherapy drug pembrolizumab, two chemotherapy drugs (carboplatin and paclitaxel), and radiation for people with early-stage anal cancer who cannot take the usual chemotherapy. The goal is to see if this approach is safe and effective as an alternative treatment.
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Hear when a new Anal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.